Shuttle pharma receives notice of nasdaq non-compliance with listing rule 5250(c)(1)

Gaithersburg, md., aug. 26, 2024 (globe newswire) -- shuttle pharmaceuticals holdings, inc. (nasdaq: shph) (“shuttle pharma” or the “company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (rt), today reports that it received formal notice (the “notice”) from the nasdaq stock market llc (“nasdaq”) that it is not in compliance with nasdaq listing rule 5250(c)(1) (the “listing rule”) as a result of the company's failure to timely file its quarterly report on form 10-q for the period ended june 30, 2024 (the “q2 quarterly report”).
NDAQ Ratings Summary
NDAQ Quant Ranking